Stroke patients treated with intravenous alteplase (Activase) did not have more intracranial hemorrhages if they had recently taken non-vitamin K antagonist oral anticoagulants (NOACs), according to ...

Purpose. The efficacy and safety of i.v. alteplase up to 4.5 hours after acute ischemic stroke (AIS) onset were evaluated. Summary. Stroke is the leading cause of disability in the elderly, and i.v.

A three month treatment with 300 mg IV aspirin does not improve the functional outcome of alteplase-treated acute ischemic stroke patients. However, the risk of developing SICH and SAEs is enhanced.

In 2001, the US Food and Drug Administration approved recombinant tissue plasminogen activator (alteplase, Cathflo Activase) to reestablish patency of central catheters occluded, presumably, by a ...

Before 1998, urokinase was considered standard therapy for the management of occluded hemodialysis catheters. The dose of 5000 units per port appears on the FDA-approved labeling for urokinase. Bolus ...

Researchers have found in a new study that adjunctive intra-arterial alteplase administered after successful thrombectomy may ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Intracoronary alteplase administered during primary PCI for STEMI does not reduce microvascular ...

DALLAS -- Dual antiplatelet therapy (DAPT) proved non-inferior to IV alteplase in Chinese patients with minor non-disabling stroke, a researcher reported. In the ARAMIS trial of patients with acute ...

IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more. Activase is a recombinant ...